The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 analogues and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. https://hassanymqo039629.wikicommunications.com/6830274/glp_3_retatrutide_a_comparative_analysis